ALKS News
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI (olanzapine...
Business Wire
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI (olanzapine...
Business Wire
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time...
Business Wire
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Alkermes (ALKS) delivered earnings and revenue surprises of +212.50% and +3.05%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the companys investor relations website at https://investor.alkermes.com. Alkermes will host a...
Business Wire
Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the companys investigational orexin 2 receptor (OX2R...
Business Wire
Alnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the companys third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...
Business Wire
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks